KR960705919A - 제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain) - Google Patents

제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain) Download PDF

Info

Publication number
KR960705919A
KR960705919A KR1019960702618A KR19960702618A KR960705919A KR 960705919 A KR960705919 A KR 960705919A KR 1019960702618 A KR1019960702618 A KR 1019960702618A KR 19960702618 A KR19960702618 A KR 19960702618A KR 960705919 A KR960705919 A KR 960705919A
Authority
KR
South Korea
Prior art keywords
jeryl
lynn
parotiditis
virus strain
homologous
Prior art date
Application number
KR1019960702618A
Other languages
English (en)
Other versions
KR100362051B1 (ko
Inventor
마우라이스 하포드 니겔
데시리 알버트 콜라우 브리게트
디델레츠 진
Original Assignee
쟝 슈테펜
스미쓰클라인 비참 바이올로지칼스 (에스.에이.)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939323820A external-priority patent/GB9323820D0/en
Priority claimed from GB9406480A external-priority patent/GB9406480D0/en
Application filed by 쟝 슈테펜, 스미쓰클라인 비참 바이올로지칼스 (에스.에이.) filed Critical 쟝 슈테펜
Publication of KR960705919A publication Critical patent/KR960705919A/ko
Application granted granted Critical
Publication of KR100362051B1 publication Critical patent/KR100362051B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0015—Combination vaccines based on measles-mumps-rubella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18761—Methods of inactivation or attenuation
    • C12N2760/18762—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36211—Rubivirus, e.g. rubella virus
    • C12N2770/36234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

본 발명은 귀밑샘염 바이러스 Jeryl-Lynn 균주로부터 유도된 상동 순수 분리균으로 이루어진 새로운 귀밑샘염 백신에 관한 것이다. 본 발명의 바람직한 구체예에서, 상기 백신은, 공지된 상업적 백신 보다 더 높은 혈청 전환 및 향체 역가를 생성한다.

Description

제릴-린 (JERYL-LYNN) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(VACCINE AGAINST MUMPS CONTAINING A JERYL-LYNN VIRUS STRAIN)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 SH 유전자 및 SH HN 유전자간 영역상의 Jeryl Lynn 분리균 cDNA 서열.

Claims (8)

  1. SH 유전자 및 HN 유전자의 N 말단이 제1도에 제시된 핵산 서열로 이루어지는 것을 특징으로 하는 감쇄된 Jeryl-Lynn 귀밑샘염 바이러스 균주.
  2. 상동인 면역원성 Jeryl-Lynn 분리균으로 이루어진 귀밑샘염 백신.
  3. 제2항에 있어서, 제1항의 상동 분리균으로 이루어진 것을 특징으로 하는 귀밑샘염 백신.
  4. 상동인 면역원성 Jeryl-Lynn 분리균 및 하나 이상의 감쇄된 홍역 바이러스, 또는 감쇄된 풍진 바이러스 또는 치사된 홍역 또는 풍진 바이러스, 또는 이러한 바이러스의 하위단위체로 이루어지는 것을 특징으로 하는 조합 백신.
  5. 제3항 또는 4항에 있어서, 수두 또는 대상포진에 대한 보호용 제제를 포함하는 것을 특징으로 하는 백신.
  6. 적합한 세포 주 상에서 Jeryl-Lynn 제조액을 패시징시키고, a) 제한 회석; 또는 b) 각각의 플라크 분리의 단계를 사용하여 순수 배양을 선택하는 것으로 이루어지는 것을 특징으로 하는 상동인 면역원성 Jeryl-Lynn 분리균을 생성시키는 방법.
  7. 의학적 사용을 위한 상동 면역원성 Jeryl-Lynn 분리균.
  8. 효과량의 제2 내지 5항 중 어느 한 항에 따른 백신을 포유 동물에 투여하는 것을 이루어진, 귀밑샘염 감염에 민감한 포유 동물내에서 면역성을 유도하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702618A 1993-11-19 1994-11-15 제릴-린(jeryl-lynn)바이러스균주를함유하는유행성이하선염에대한백신 KR100362051B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB939323820A GB9323820D0 (en) 1993-11-19 1993-11-19 Vaccine
GB9323820.1 1993-11-19
GB9323820.2 1993-11-19
GB9406480A GB9406480D0 (en) 1994-03-31 1994-03-31 Vaccine
GB9406480.5 1994-03-31

Publications (2)

Publication Number Publication Date
KR960705919A true KR960705919A (ko) 1996-11-08
KR100362051B1 KR100362051B1 (ko) 2003-04-11

Family

ID=26303889

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702618A KR100362051B1 (ko) 1993-11-19 1994-11-15 제릴-린(jeryl-lynn)바이러스균주를함유하는유행성이하선염에대한백신

Country Status (20)

Country Link
US (4) US6024962A (ko)
EP (2) EP1484391A1 (ko)
JP (1) JPH09504954A (ko)
KR (1) KR100362051B1 (ko)
CN (2) CN1150819A (ko)
AT (1) ATE266090T1 (ko)
AU (1) AU687922B2 (ko)
CA (1) CA2176929C (ko)
CY (2) CY2540B1 (ko)
DE (3) DE122007000003I2 (ko)
DK (1) DK0729509T3 (ko)
ES (1) ES2219658T3 (ko)
HK (1) HK1012421A1 (ko)
LU (1) LU91458I2 (ko)
NL (1) NL300336I2 (ko)
NZ (1) NZ276102A (ko)
PT (1) PT729509E (ko)
SG (1) SG52780A1 (ko)
SI (1) SI0729509T1 (ko)
WO (1) WO1995014083A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687922B2 (en) 1993-11-19 1998-03-05 Smithkline Beecham Biologicals (Sa) Vaccine against mumps containing a jeryl-lynn virus strain
JP2003506039A (ja) * 1999-08-02 2003-02-18 ワイス ｃＤＮＡからの流行性耳下腺炎ウイルスのレスキュー
DK3274447T3 (da) * 2015-03-27 2020-01-27 Cadila Healthcare Ltd Rekombinant fåresygevirus jeryl lynn 2 baseret vaccine
RU2750818C1 (ru) * 2020-11-19 2021-07-05 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова Вирусный штамм для получения аттенуированной живой культуральной вакцины для профилактики и лечения опоясывающего герпеса для взрослого населения
CN114457046A (zh) * 2022-02-16 2022-05-10 科兴（大连）疫苗技术有限公司 一种稀释法传代纯化腮腺炎病毒的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3555149A (en) 1968-07-05 1971-01-12 Merck & Co Inc Mumps vaccine and its preparation
US4337242A (en) 1980-02-05 1982-06-29 Merck & Co., Inc. Vaccine stabilizer containing L-glutamic acid and L-arginine
JP3026029B2 (ja) * 1991-04-26 2000-03-27 財団法人阪大微生物病研究会 組換え水痘ウイルスとその作製法
AU687922B2 (en) 1993-11-19 1998-03-05 Smithkline Beecham Biologicals (Sa) Vaccine against mumps containing a jeryl-lynn virus strain

Also Published As

Publication number Publication date
DE122007000003I1 (de) 2007-05-24
CY2540B1 (en) 2006-06-28
CA2176929A1 (en) 1995-05-26
US20020018784A1 (en) 2002-02-14
JPH09504954A (ja) 1997-05-20
CN101948816A (zh) 2011-01-19
LU91458I2 (fr) 2008-08-25
NL300336I2 (nl) 2009-01-05
DE69433760D1 (de) 2004-06-09
NL300336I1 (nl) 2008-04-01
KR100362051B1 (ko) 2003-04-11
SI0729509T1 (en) 2004-08-31
CN1150819A (zh) 1997-05-28
US6899884B2 (en) 2005-05-31
US20030095984A1 (en) 2003-05-22
CY2008005I2 (el) 2018-01-10
CA2176929C (en) 2002-04-30
AU687922B2 (en) 1998-03-05
DE69433760T2 (de) 2005-05-12
CY2008005I1 (el) 2012-01-25
ATE266090T1 (de) 2004-05-15
US6656476B2 (en) 2003-12-02
EP0729509B1 (en) 2004-05-06
DK0729509T3 (da) 2004-08-16
WO1995014083A1 (en) 1995-05-26
EP1484391A1 (en) 2004-12-08
PT729509E (pt) 2004-09-30
AU8144194A (en) 1995-06-06
SG52780A1 (en) 1998-09-28
US20040120969A1 (en) 2004-06-24
US6024962A (en) 2000-02-15
NZ276102A (en) 1998-04-27
DE122007000003I2 (de) 2011-01-13
HK1012421A1 (en) 1999-07-30
ES2219658T3 (es) 2004-12-01
EP0729509A1 (en) 1996-09-04

Similar Documents

Publication Publication Date Title
Ennis et al. HLA-restricted virus-specific cytotoxic T-lymphocyte responses to live and inactivated influenza vaccines
Wiktor et al. Antigenic properties of rabies virus components
Cox et al. Rabies virus glycoprotein. II. Biological and serological characterization
ES2016426A6 (es) Un procedimiento para detectar la presencia de anticuerpos frente a virus del sida en el suero humano.
ATE395932T1 (de) Rekombinanter immunschwächepoxvirus
RU2000116260A (ru) Вакцины с адъювантом ltb
RU93058614A (ru) Мутант вируса герпеса, композиции, диагностические наборы, способы определения инфекции
ATE355375T1 (de) Bakterioferritin aus helicobacter pylori
BG98522A (en) Peptides including cytotoxic t-lymphocytic response to the virus of hepatite b
BR9610343A (pt) Vacinas de subtipos múltiplos para fiv
Dietzschold et al. Serological characterization of the three major proteins of vesicular stomatitis virus
KR960705919A (ko) 제릴-린(jeryl-lynn) 바이러스 균주를 함유하는 유행성 귀밑샘염에 대한 백신(vaccine against mumps containing a jeryl-lynn virus strain)
ATE82687T1 (de) Gegen pseudomonas aeruginosa infektionen wirksame praeparationen und verfahren zu ihrer herstellung.
EP0865296A1 (en) Influenza vaccine
DE69101646T2 (de) Vakzine gegen Coccidiose.
Laver et al. Diversity of the antibody response to the different antigenic determinants on the hemagglutinin subunits of influenza viruses
DK8789A (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
ATE283065T1 (de) Mehrzweckvakzine gegen umhüllte viren
US20230144060A1 (en) MERS-CoV VACCINE
DK0787796T3 (da) Beskyttende epitoper fra adenylat-cyclase-hæmolysin (AC-Hly) og deres anvendelse til behandling eller forebyggelse af Bordetella-infektioner
Sachs et al. Cytomegalovirus vaccine: persistence of humoral immunity following immunization of renal transplant candidates
George 4th et al. Identification of a T-cell epitope on the circumsporozoite protein of Plasmodium vivax
Webster et al. Efficacy of equine influenza vaccines for protection against A/Equine/Jilin/89 (H3N8)—a new equine influenza virus
Merza et al. Characterization of an iscom prepared with envelope glycoproteins of bovine herpesvirus type 1
Takada et al. Induction of protective antibody responses against pseudorabies virus by intranasal vaccination with glycoprotein B in mice

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20131030

Year of fee payment: 12

FPAY Annual fee payment

Payment date: 20141030

Year of fee payment: 13

EXPY Expiration of term